モノクローナル抗体の共同研究・ライセンシング契約（2019年～2024年）

当レポートでは、モノクローナル抗体の共同研究・ライセンシング契約について調査し、企業がどのように、またなぜモノクローナル抗体の契約を行うかに関する詳細な理解と分析を提供しています。

目次

エグゼクティブサマリー

第1章 イントロダクション

第2章 モノクローナル抗体契約の動向

• イントロダクション
• 過去数年のモノクローナル抗体契約
• もっとも活発なモノクローナル抗体契約企業
• モノクローナル抗体契約：契約タイプ別
• モノクローナル抗体契約：治療領域別
• モノクローナル抗体契約：産業部門別
• モノクローナル抗体契約の契約条件
  • モノクローナル抗体契約のヘッドライン金額
  • モノクローナル抗体契約の前払い
  • モノクローナル抗体契約のマイルストーン払い
  • モノクローナル抗体のロイヤリティ料率

第3章 主なモノクローナル抗体契約

• イントロダクション
• 金額で上位のモノクローナル抗体契約

第4章 もっとも活発なモノクローナル抗体契約企業

• イントロダクション
• もっとも活発なモノクローナル抗体契約企業
• もっとも活発なモノクローナル抗体契約企業のプロファイル

第5章 モノクローナル抗体契約契約ディレクトリ

• イントロダクション
• モノクローナル抗体契約契約ディレクトリ

第6章 モノクローナル抗体契約：技術タイプ別

• 契約ディレクトリ
• 契約ディレクトリ - モノクローナル抗体契約：企業別（A-Z）
• 契約ディレクトリ - モノクローナル抗体契約：契約タイプ別
• 契約ディレクトリ - モノクローナル抗体契約：治療領域別
• 契約タイプの定義
• Biopharma Research Ltdについて
• Current Partnering
• Current Agreements
• Current Partneringからの近年のレポートのタイトル

Monoclonal Antibody Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the monoclonal antibody deals entered into by the world's leading biopharma companies.

Fully revised and updated, the report provides details of monoclonal antibody deals from 2019 to 2024.

The report provides a detailed understanding and analysis of how and why companies enter monoclonal antibody deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 639 monoclonal antibody deals announced since 2019 including financial terms where available including links to online deal records of actual monoclonal antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of monoclonal antibody dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in monoclonal antibody dealmaking since 2019.

Chapter 3 provides an overview of the leading monoclonal antibody deals since 2019. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in monoclonal antibody dealmaking with a brief summary followed by a comprehensive listing of monoclonal antibody deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of monoclonal antibody deals signed and announced since Jan 2019, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of monoclonal antibody partnering deals signed and announced since Jan 2019. The chapter is organized by specific monoclonal antibody technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in monoclonal antibody deal making since 2019.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Monoclonal Antibody Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2019
• Browse monoclonal antibody collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Monoclonal Antibody Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of monoclonal antibody trends and structure of deals entered into by leading biopharma companies worldwide.

Monoclonal Antibody Collaboration and Licensing Deals includes:

• Trends in monoclonal antibody dealmaking in the biopharma industry
• Directory of monoclonal antibody deal records covering pharmaceutical and biotechnology
• The leading monoclonal antibody deals by value
• Most active monoclonal antibody licensing dealmakers
• Monoclonal Antibody Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in monoclonal antibody dealmaking

• 2.1. Introduction
• 2.2. Monoclonal antibody deals over the years
• 2.3. Most active monoclonal antibody dealmakers
• 2.4. Monoclonal antibody deals by deal type
• 2.5. Monoclonal antibody deals by therapy area
• 2.6. Monoclonal antibody deals by industry sector
• 2.7. Deal terms for monoclonal antibody deals
  • 2.7.1 Monoclonal antibody deals headline values
  • 2.7.2 Monoclonal antibody deal upfront payments
  • 2.7.3 Monoclonal antibody deal milestone payments
  • 2.7.4 Monoclonal antibody royalty rates

Chapter 3 - Leading monoclonal antibody deals

• 3.1. Introduction
• 3.2. Top monoclonal antibody deals by value

Chapter 4 - Most active monoclonal antibody dealmakers

• 4.1. Introduction
• 4.2. Most active monoclonal antibody dealmakers
• 4.3. Most active monoclonal antibody deals company profiles

Chapter 5 - Monoclonal antibody contracts dealmaking directory

• 5.1. Introduction
• 5.2. Monoclonal antibody contracts dealmaking directory

Chapter 6 - Monoclonal antibody dealmaking by technology type

• Deal directory
• Deal directory - Monoclonal antibody deals by company A-Z
• Deal directory - Monoclonal antibody deals by deal type
• Deal directory - Monoclonal antibody deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Monoclonal antibody deals since 2019
• Figure 2: Active monoclonal antibody dealmaking activity - 2019 - 2024
• Figure 3: Monoclonal antibody deals by deal type since 2019
• Figure 4: Monoclonal antibody deals by therapy area since 2019
• Figure 5: Monoclonal antibody deals by industry sector since 2019
• Figure 6: Monoclonal antibody deals with a headline value
• Figure 7: Monoclonal antibody deals with an upfront value
• Figure 8: Monoclonal antibody deals with a milestone value
• Figure 9: Monoclonal antibody deals with a royalty rate value
• Figure 10: Top monoclonal antibody deals by value since 2019
• Figure 11: Most active monoclonal antibody dealmakers 2019 - 2024
• Figure 12: Monoclonal antibody deals by technology type since 2019